Celldex Therapeutics Inc CLDX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $38.98
- Day Range
- $37.81–39.19
- 52-Week Range
- $19.72–40.30
- Bid/Ask
- $37.40 / $41.00
- Shares Outstanding
- 78.49M
- Market Cap
- $3.07B
- Volume/Avg
- 694,010 / 955,344
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3,064.70
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 198
- Website
- https://www.celldex.com
Valuation
|
Metric
|
CLDX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 5.83 |
Price/Sales | 3,064.70 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CLDX
|
|---|---|
Quick Ratio | 8.78 |
Current Ratio | 8.92 |
Interest Coverage | — |
Quick Ratio
CLDX
Profitability
|
Metric
|
CLDX
|
|---|---|
Return on Assets (Normalized) | −39.09% |
Return on Equity (Normalized) | −42.21% |
Return on Invested Capital (Normalized) | −42.02% |
Return on Assets
CLDX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|fgN%w# | LOCK|?NL^Y | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|r&!LBj | LOCK|jq>! | $70B | |||
| argenx SE ADR
ARGX
| LOCK|QZW^Xr | LOCK|Rs | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|<&!#DG | LOCK|m#k^! | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|!$&P<qd | LOCK|#Y | $36B | |||
| Moderna Inc
MRNA
| LOCK|?M&sq!D | LOCK|$PW | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|kt%qf@? | LOCK|@>pm | $25B | |||
| Incyte Corp
INCY
| LOCK|GLH!@SV | LOCK|z? | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|^MT!vgN | LOCK|B%V | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|blJ<!Y^ | LOCK|mYr | $17B |
United States